Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20+ billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike speeding toward the market. The second volume of Kalorama’s ongoing market study on anti-infectives tackles this large and dynamic segment with a global report on the clinical, regulatory, business, and even political forces that are shaping the rapidly changing antibiotic market.
Don't forget to check out Volumes I and III of this exciting series! Purchase two volumes and save 10% or purchase the entire series and save 20%!
Volume I: The World Market for Antifungal Medications
Volume III: The World Market for Antiviral Medications
The World Market for Anti-infectives Series - Volumes I-III
Resistance Issues and Unmet Need Drive Antibiotic Market Toward $30 Billion
New York, January 21, 2003 /PR Newswire
— The worldwide market for antibacterial drugs will grow to almost $30 billion by 2006, according to a new study released today from Kalorama Information. Antibiotic-resistant strains of bacteria are challenging the industry to develop new drugs and creating sizable market potential for both large and small companies, according to the report.
World infection rates are on the rise on account of the AIDS pandemic and the effects of urbanization, globalization, and demographic shifts. In addition, troublesome antibiotic resistance is making many of the first-line treatments obsolete, adding to enormous unmet need for new, more potent drugs.
"Part of the problem is that there have been almost no truly new types of antibiotics commercialized in recent history," notes Steven Heffner, Acquisitions Editor at Kalorama Information. "Rather, ‘new’ antibiotics have mainly been modifications of the same class of compounds. And even Zyvox, the first truly new antibiotic class [oxazolidinones] to be developed in more than 30 years, induced detectable bacterial resistance within two years of its commercial release."
Antibiotic resistance and several impending big-name patent expirations are creating an increasingly competitive development environment, according to the report. Big pharma companies, small biotech concerns, and even many research institutions are in the hunt for new weapons to fight troublesome bacterial infections, with several notable successes on the horizon.
The study, The Worldwide Market for Antibacterial Drugs, represents the second volume of an ongoing study of anti-infective drug markets by Kalorama. The study discusses market size, market share, epidemiology of major infections, patent expirations, and pipeline products, as well as clinical and business trends affecting the industry. The first volume covered antifungal drugs, and the third volume, due out in March, will cover antiviral medications.
About Kalorama Information
Kalorama Information, an imprint of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Steven Heffner at 212-807-2634 or firstname.lastname@example.org, or visit www.KaloramaInformation.com.
MarketResearch.com is the leading provider of global market intelligence products and services. With over 50,000 research publications from 350 research publishers, we offer instant online access to the world’s most extensive database of expert insights on global industries. Updated daily. For more information, contact Alison Williams at 301-468-3650 x203 or email@example.com, or visit www.MarketResearch.com.
Chapter One: Executive Summary
Antibiotic Medications Overview
Market Orientation in Brief
Issues Driving the Market
Scope and Methodology
Chapter Two: Introduction
Types of Compounds
Drug Use Patterns
Chapter Three: Emerging Therapies
In the Pipeline
Drug and Patent Exclusivity
Chapter Four: The World Market For Antibiotics
Markets by Geographic Region
Market Share by Type of Drug
Major Market Drugs and Players
Pediatric Antibiotic Market
Chapter Five: Company Profiles
List of Exhibits
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook